{"doi":"10.1016/j.celrep.2024.114746","title":"Ceramide synthesis inhibitors prevent lipid-induced insulin resistance through the DAG-PKCε-insulin receptorT1150 phosphorylation pathway","abstract":"Inhibition of the ceramide synthetic pathway with myriocin or an antisense oligonucleotide (ASO) targeting dihydroceramide desaturase (DES1) both improved hepatic insulin sensitivity in rats fed either a saturated or unsaturated fat diet and was associated with reductions in both hepatic ceramide and plasma membrane (PM)- sn -1,2-diacylglycerol (DAG) content. The insulin sensitizing effects of myriocin and Des1 ASO were abrogated by acute treatment with an ASO against DGAT2, which increased hepatic PM- sn -1,2-DAG but not hepatic C16 ceramide content. Increased PM- sn -1,2-DAG content was associated with protein kinase C (PKC)ε activation, increased insulin receptor (INSR) T1150 phosphorylation leading to reduced insulin-stimulated INSR Y1152 /Akt S473 phosphorylation, and impaired insulin-mediated suppression of endogenous glucose production. These results demonstrate that inhibition of de novo ceramide synthesis by either myriocin treatment or DES1 knockdown protects against lipid-induced hepatic insulin resistance through a C16 ceramide-independent mechanism and that they mediate their effects to protect from lipid-induced hepatic insulin resistance via the PM- sn -1,2-DAG-PKCε-INSR T1150 phosphorylation pathway.","journal":"Cell Reports","year":2024,"id":422358,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":27,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9541,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2024-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":249693,"name":"Dongyan Zhang","orcid":"0000-0002-4036-3987","position":1,"is_corresponding":false},{"id":1216050,"name":"Yumin Ma","orcid":"0000-0001-9271-3363","position":2,"is_corresponding":false},{"id":256420,"name":"Rafael Calais Gaspar","orcid":"0000-0002-2208-3527","position":3,"is_corresponding":false},{"id":257346,"name":"Mario Kahn","orcid":null,"position":4,"is_corresponding":false},{"id":252719,"name":"Ali Nasiri","orcid":null,"position":5,"is_corresponding":false},{"id":1216051,"name":"Sue Murray","orcid":"0000-0002-7302-624X","position":6,"is_corresponding":false},{"id":256428,"name":"Varman T. Samuel","orcid":"0000-0001-8992-7707","position":7,"is_corresponding":false},{"id":232241,"name":"Gerald I. Shulman","orcid":"0000-0003-1529-5668","position":8,"is_corresponding":false},{"id":1216049,"name":"Weiwei Xu","orcid":"0000-0001-8310-2632","position":0,"is_corresponding":true}],"reference_count":56,"raw_metadata":null,"created_at":"2026-07-19T01:57:46.393290Z","pmid":"39302831","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}